immunogen inc  product pipeline review   about us solutions resources ebookswhite papers slideshares videos blog contact us register log in my account logout browse research my cart menu   close   x browse about us solutions resources contact us log out register log in life sciences»pharmaceuticals»pharmaceuticals company reports immunogen inc  product pipeline review   lowest prices guaranteed length publisher published date sku from   pages global markets direct august  gmd lowest prices guaranteed price from  length  pages publisher global markets direct published date august  sku gmd table of contents close window table of contents immunogen inc  product pipeline review   printer format global markets direct immunogen inc snapshot immunogen inc overview key information key facts immunogen inc  research and development overview key therapeutic areas immunogen inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities immunogen inc  pipeline products glance immunogen inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities immunogen inc  early stage pipeline products preclinical productscombination treatment modalities immunogen inc  drug profiles coltuximab ravtansine product description mechanism of action rd progress imgn product description mechanism of action rd progress mirvetuximab soravtansine product description mechanism of action rd progress huher product description mechanism of action rd progress imgn product description mechanism of action rd progress imgn product description mechanism of action rd progress immunogen inc  pipeline analysis immunogen inc  pipeline products by target immunogen inc  pipeline products by route of administration immunogen inc  pipeline products by molecule type immunogen inc  pipeline products by mechanism of action immunogen inc  recent pipeline updates immunogen inc  dormant projects immunogen inc  discontinued pipeline products discontinued pipeline product profiles ave ave cantuzumab ravtansine coltuximab ravtansine imgn lorvotuzumab mertansine oncolysin b immunogen inc  company statement immunogen inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesimmunogen inc key information immunogen inc key facts immunogen inc  pipeline by indication  immunogen inc  pipeline by stage of development  immunogen inc  monotherapy products in pipeline  immunogen inc  partnered products in pipeline  immunogen inc  partnered products combination treatment modalities  immunogen inc  phase ii  immunogen inc  phase i  immunogen inc  preclinical  immunogen inc  pipeline by target  immunogen inc  pipeline by route of administration  immunogen inc  pipeline by molecule type  immunogen inc  pipeline products by mechanism of action  immunogen inc  recent pipeline updates  immunogen inc  dormant developmental projects immunogen inc  discontinued pipeline products  immunogen inc subsidiaries list of figuresimmunogen inc  pipeline by top  indication  immunogen inc  pipeline by stage of development  immunogen inc  monotherapy products in pipeline  immunogen inc  partnered products in pipeline  immunogen inc  pipeline by top  target  immunogen inc  pipeline by top  route of administration  immunogen inc  pipeline by top  molecule type  immunogen inc  pipeline products by top  mechanism of action  description close window description immunogen inc  product pipeline review   printer format global markets direct immunogen inc  product pipeline review  summaryglobal markets direct’s ‘immunogen inc  product pipeline review  ’ provides an overview of the immunogen inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of immunogen inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of immunogen inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of immunogen inc’s human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones special feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statement latest news and deals relating to the immunogen inc’s pipeline productsreasons to buyevaluate immunogen inc’s strategic position with total access to detailed information on its product pipelineassess the growth potential of immunogen inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the immunogen inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of immunogen inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of immunogen incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of immunogen inc and identify potential opportunities in those areasavoid intellectual property rights related issues search inside this report close window search inside this report online download  purchase site license  purchase global site license  purchase   research assistance us  intl  download our ebook how to succeed using market research learn how to effectively navigate the market research process to help guide your organization on the journey to success download ebook share this report other tasks printer format order by fax currency converter immunogen inc private company information  bloomberg july    am et biotechnology company overview of immunogen inc snapshot people company overview immunogen inc a clinicalstage biotechnology company develops targeted anticancer therapeutics the company develops its products using its antibodydrug conjugate adc technology the company’s product candidates include mirvetuximab soravtansine an adc targeting folatereceptor alpha for the treatment of platinumresistant ovarian cancer imgn an adc that is in phase b clinical trials for bcell malignancies coltuximab ravtansine which is in phase  trials for bcell malignancies imgn that is in phase  clinical trials for the treatment of acute myeloid leukemia aml and imgn a preclinical cdtargeting adc for the treatment of hematological malignancies includi immunogen inc a clinicalstage biotechnology company develops targeted anticancer therapeutics the company develops its products using its antibodydrug conjugate adc technology the company’s product candidates include mirvetuximab soravtansine an adc targeting folatereceptor alpha for the treatment of platinumresistant ovarian cancer imgn an adc that is in phase b clinical trials for bcell malignancies coltuximab ravtansine which is in phase  trials for bcell malignancies imgn that is in phase  clinical trials for the treatment of acute myeloid leukemia aml and imgn a preclinical cdtargeting adc for the treatment of hematological malignancies including aml immunogen inc has collaborations with roche bayer healthcare ag sanofi biotest ag novartis institutes for biomedical research inc eli lilly and company amgen takeda pharmaceutical company limited merck and cytomx therapeutics inc immunogen inc was founded in  and is headquartered in waltham massachusetts detailed description  winter streetwaltham ma united statesfounded in  employees phone  wwwimmunogencom key executives for immunogen inc mr mark j enyedy chief executive officer president and director age  total annual compensation k mr david b johnston chief financial officer and executive vice president age  total annual compensation k dr richard j gregory phd chief scientific officer and executive vice president age  total annual compensation k dr anna berkenblit md mmsc chief medical officer and vice president age  total annual compensation k compensation as of fiscal year  immunogen inc key developments immunogen inc to report q  results on jul   jul   immunogen inc announced that they will report q  results at  pm gmt standard time on jul   immunogen inc q  earnings call jul   jul   immunogen inc q  earnings call jul   immunogen inc presents data from phase i study of imgn in acute myeloid leukemia jun   immunogen inc presented data from the ongoing phase  study evaluating single agent imgn in patients with relapsed or refractory adult acute myeloid leukemia aml whose tumors express cd these results were presented in a poster presentation on june   at the ndcongress of the european hematology association eha in madrid spain imgn combines a highaffinity humanized anticd antibody with one of immunogen’s novel indolinobenzodiazepine payloads called igns which alkylate dna without crosslinking resulting in potent antileukemia activity with relative sparing of normal hematopoietic progenitor cells safety pharmacokinetic pk and pharmacodynamic pd data as well as initial antileukemia activity for imgn through dose level seven were presented at eha key findings included no dlts have been observed through dose level seven with reported adverse events consistent with the underlying disease no increase in the nature frequency or severity of any treatmentemergent adverse event has been reported with escalating doses and no evidence of cumulative toxicity has been observed with repeated dosing favorable pkpd reveal prolonged exposure and cd saturation at dose levels six and seven initial antileukemia activity was observed at dose levels six and seven in patients who failed intensive frontline therapy the phase  trial is designed to establish the maximum tolerated dose and determine the recommended phase  dose for imgn administered as monotherapy the trial is also intended to evaluate safety and tolerability and characterize pk pd and preliminary antileukemia activity in relapsed or refractory aml dose escalation continues preclinical data for imgn were also presented at eha showing the agent is highly active in multiple aml xenograft models and is welltolerated in preclinical repeat dosing regimens findings from the preclinical evaluation provided the foundation for the clinical evaluation of imgn in aml similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target mergeracquisition may   immunogen inc imgndebio  request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact immunogen inc please visit wwwimmunogencom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close imgn key statistics  immunogen inc financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close immunogen inc nasdaq imgn go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus immunogen inc after hours  quotes are delayed by  min jul    pm imgn quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description immunogen inc is a biotechnology company which develops novel anticancer therapeutics using its antibodydrug conjugate technology its product candidates include mirvetuximab soravtansine coltuximab ravtansine and kadcyla  the company was founded in march  and is headquartered in waltham  immunogen inc is a biotechnology company which develops novel anticancer therapeutics using its antibodydrug conjugate technology its product candidates include mirvetuximab soravtansine coltuximab ravtansine and kadcyla  the company was founded in march  and is headquartered in waltham ma valuation pe current  pe ratio with extraordinary items  price to sales ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on total capital  return on invested capital  capital structure total debt to total capital  total debt to total assets  longterm debt to total capital  officers and executives name age officer since title mr mark j enyedy   president chief executive officer  director mr david b johnston   chief financial officer  executive vice president dr thomas ryll   vice presidenttechnical operations dr anna berkenblit   chief medical officer  vice president dr richard j gregory   chief scientific officer  executive vp insider actions – purchase – sale  – number of transactions  date name shares transaction value  peter j williams vp business development    award at  per share   mark j enyedy chief executive officer director    award at  per share   richard j gregory executive vp  cso    award at  per share   david b johnston chief financial officer    award at  per share   craig barrows vicepresidentgeneral counsel    award at  per share   anna berkenblit vp  chief medical officer    award at  per share   theresa g wingrove vp of regulatory affairs    award at  per share   peter j williams vp business development    award at  per share   mark alan goldberg director    acquisition at  per share   mark j enyedy chief executive officer director    acquisition at  per share   richard j gregory executive vp  cso    acquisition at  per share   david b johnston chief financial officer    acquisition at  per share   craig barrows vicepresidentgeneral counsel    acquisition at  per share   john m lambert executive vice president    acquisition at  per share   daniel m junius director    derivativenonderivative trans at  per share   john m lambert executive vice president    derivativenonderivative trans at  per share   john m lambert executive vice president    derivativenonderivative trans at  per share   john m lambert executive vice president    disposition at  per share   john m lambert executive vice president    derivativenonderivative trans at  per share   richard j gregory executive vp  cso    disposition at  per share   daniel m junius director    disposition at  per share   john m lambert executive vice president    disposition at  per share   daniel m junius director    derivativenonderivative trans at  per share   john m lambert executive vice president    derivativenonderivative trans at  per share  newslatestcompanyusimgn marketwatch news on imgn three biotech companies to watch ahead of earnings  pm july    harry boxer immunogen stock price target raised to  from  at rbc capital  am july    tomi kilgore immunogen upgraded to outperform from sector perform at rbc capital  am july    tomi kilgore dow industrials sustain the june breakout sp  pulls in to the range  am june    michael ashbaugh stocks close higher as tech economic data power rebound  pm may    barbara kollmeyer immunogen downgraded to sector perform from outperform at rbc capital  am may    tomi kilgore immunogen stock price target cut to  from  at rbc capital  am may    tomi kilgore charting the us markets’ next tests  am aug    michael ashbaugh immunogen downgraded to hold from buy at cantor fitzgerald  am aug    tomi kilgore immunogen stock price target raised to  from  at cantor fitzgerald  am aug    tomi kilgore six stocks to watch  pm july    the trading deck  stocks to watch  pm june    the trading deck immunogen bristol make strides in cancer battle  pm june    russ britt dollar won’t crash the sp  as long as the fed stays friendly  am march    barbara kollmeyer update immunogens stock jumps after licensing deal with japans takeda  am march    tomi kilgore immunogens stock soars  in premarket trade after licensing deal  am march    tomi kilgore immunogens stock plunges after roches disappointing trial results prompts downgrade  pm dec    tomi kilgore roche hit by failure of trial for cancer drug kadcyla  am dec    neil maclucas biotech starts recovery as etfs finish day firmly in the black  pm april    russ britt jive software stampscom down after hours  pm nov    marketwatch loading more headlines newsnonmarketwatchcompanyusimgn other news on imgn why shares of immunogen inc shot up today  pm july    motley fool immunogens imgn ceo mark enyedy on q  results  earnings call transcript  pm july    seeking alpha despite decline in global markets several stocks are jumping  am july    gurufocuscom immunogen imgn reports narrowerthanexpected q loss  am july    zackscom immunogen net loss imroves in q updates guidance shares ahead  premarket  am july    seeking alpha four stocks breaking out  pm july    benzingacom why immunogen inc jumped higher today  pm july    motley fool value investment stock selections using forensic analysis  july  am july    seeking alpha is a beat in the cards for immunogen imgn in q earnings  am july    zackscom immunogen finally moving forward  pm july    seeking alpha can immunogens lead pipeline cancer candidate boost growth  pm july    zackscom heres why immunogen inc shares exploded  higher in june  pm july    motley fool immunogens turnaround is in fullswing following asco presentations  am july    benzingacom immunogen higher as rbc comes around  am july    seeking alpha top analyst upgrades and downgrades autozone o’reilly automotive immunogen medtronic nike oncosec schlumberger and more  am july    wallstcom biotechs head higher ahead of q earnings dump  pm july    seeking alpha penny stocks to watch for july   pm june    investopediacom immunogen  reentry puzzle  pm june    seeking alpha top analyst upgrades and downgrades amarin amex barrick gold cameco groupon immunogen jpmorgan whole foods and more  am june    wallstcom why immunogen inc jumped higher on monday  pm june    motley fool loading more headlines at a glance immunogen inc  winter street waltham massachusetts  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue m net income m employees  annual report for imgn newspressreleasecompanyusimgn press releases on imgn immunogen reports recent progress and second quarter  operating results  am july    businesswire  bzx investor network immunogen inc to host earnings call  am july    accesswire immunogen announces conference call to discuss its second quarter  financial results  am july    businesswire  bzx immunogen presents data from phase i study of imgn in acute myeloid leukemia  am june    businesswire  bzx todays research reports on stocks to watch exact sciences and immunogen  am june    accesswire biopharma stock breakouts with significant developments and market activity  pm june    pr newswire  prf key pharma stocks with advanced developments and breakthrough discoveries  am june    pr newswire  prf immunogen and sanofi amend license agreements  am may    businesswire  bzx immunogen announces webcast of presentation at the jefferies global healthcare conference  am may    businesswire  bzx debiopharm international sa enters the field of antibodydrug conjugates through acquisition of phase ii asset from immunogen  pm may    businesswire  bzx immunogen announces new clinical data with mirvetuximab soravtansine in ovarian cancer to be presented at  asco annual meeting  pm may    businesswire  bzx technical reports on biotech stocks  celsion incyte immunogen and catabasis pharma  am may    pr newswire  prf investor network immunogen inc to host earnings call  am may    accesswire immunogen reports recent progress and first quarter  operating results  am may    businesswire  bzx immunogen announces results from mirvetuximab soravtansine phase  firstinhuman doseescalation trial published in cancer  am may    businesswire  bzx immunogen announces conference call to discuss its first quarter  financial results  am april    businesswire  bzx todays research reports on biotech stocks to watch array biopharma and immunogen  am april    accesswire global antibody drug conjugates market analysis by drugs  pipeline drugs regulations opportunities and forecasts  by region  by country  pm april    pr newswire  prf tg therapeutics and immunogen are models of institutional investor attention  am march    accesswire immunogen presents phase  biopsy expansion cohort data at the society of gynecologic oncology annual meeting  pm march    businesswire  bzx loading more headlines log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abreakingelon musk details tesla model  pricing range atesla standard model  will cost  longrange model will cost  pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft immunogen inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports immunogen inc  product pipeline review   immunogen inc  product pipeline review   wgr  january  global  pages global markets direct description table of content sample report enquiry before buy related reports immunogen inc  product pipeline review  summaryglobal market direct’s pharmaceuticals report “immunogen inc  product pipeline review  ” provides data on the immunogen inc’s research and development focus the report includes information on current developmental pipeline complete with latest updates and features on discontinued and dormant projects this report is built using data and information sourced from global markets direct’s proprietary databases immunogen inc’s corporate website sec filings investor presentations and featured press releases both from immunogen inc and industryspecific third party sources put together by global markets direct’s team scope immunogen inc  brief immunogen inc overview including business description key information and facts and its locations and subsidiaries review of current pipeline of immunogen inc human therapeutic division overview of pipeline therapeutics across various therapy areas coverage of current pipeline molecules in various stages of drug development including the combination treatment modalities across the globe product profiles for late stage and clinical stage products of immunogen inc with complete description of the product’s developmental history mechanism of action therapeutic class target and major milestones  recent updates of the immunogen inc’s pipeline in the last quarter  key discontinued and dormant projects  latest news and deals relating to the productsreasons to buy evaluate immunogen inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of immunogen inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the immunogen inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  exploit collaboration and partnership opportunities with immunogen inc  avoid intellectual property rights related issues  explore the dormant and discontinued projects of immunogen inc and identify potential opportunities in those areas table of contentstable of contents list of tables list of figures immunogen inc snapshot immunogen inc overview key information key facts immunogen inc  research and development overview key therapeutic areas immunogen inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities pipeline products  outlicensed products outlicensed productscombination treatment modalities immunogen inc  pipeline products glance immunogen inc  clinical stage pipeline products phase i productscombination treatment modalities immunogen inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities immunogen inc  drug profiles imgn product description mechanism of action rd progress imgn product description mechanism of action rd progress imgn product description mechanism of action rd progress lorvotuzumab mertansine product description mechanism of action rd progress pc product description mechanism of action rd progress huher product description mechanism of action rd progress immunogen inc  pipeline analysis immunogen inc  pipeline products by therapeutic class immunogen inc  pipeline products by target immunogen inc  pipeline products by route of administration immunogen inc  pipeline products by molecule type immunogen inc  pipeline products by mechanism of action immunogen inc  recent pipeline updates immunogen inc  dormant projects immunogen inc  discontinued pipeline products discontinued pipeline product profiles ave ave cantuzumab ravtansine imgn lorvotuzumab mertansine oncolysin b immunogen inc  company statement immunogen inc  locations and subsidiaries head office immunogen inc  key manufacturing facilities appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesimmunogen inc key information immunogen inc key facts immunogen inc  pipeline by indication  immunogen inc  pipeline by stage of development  immunogen inc  monotherapy products in pipeline  immunogen inc  partnered products in pipeline  immunogen inc  partnered products combination treatment modalities  immunogen inc  outlicensed products in pipeline  immunogen inc  outlicensed products combination treatment modalities  immunogen inc  phase i  immunogen inc  preclinical  immunogen inc  discovery  immunogen inc  pipeline by therapeutic class  immunogen inc  pipeline by target  immunogen inc  pipeline by route of administration  immunogen inc  pipeline by molecule type  immunogen inc  pipeline products by mechanism of action  immunogen inc  recent pipeline updates  immunogen inc  dormant developmental projects immunogen inc  discontinued pipeline products  immunogen inc key manufacturing facilities list of figuresimmunogen inc  pipeline by top  indication  immunogen inc  pipeline by stage of development  immunogen inc  monotherapy products in pipeline  immunogen inc  partnered products in pipeline  immunogen inc  pipeline by top  therapeutic class  immunogen inc  pipeline by top  target  immunogen inc  pipeline by top  route of administration  immunogen inc  pipeline by top  molecule type  immunogen inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » immunogen inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report immunogen inc  product pipeline review   published by global markets direct product code  published august   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license immunogen inc  product pipeline review   published august   content info  pages description summary global markets directs immunogen inc  product pipeline review   provides an overview of the immunogen incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of immunogen incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of immunogen inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of immunogen incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the immunogen incs pipeline products reasons to buy evaluate immunogen incs strategic position with total access to detailed information on its product pipeline assess the growth potential of immunogen inc in its therapy areas of focus identify new drug targets and therapeutic classes in the immunogen incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of immunogen inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of immunogen inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of immunogen inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures immunogen inc snapshot immunogen inc overview key information key facts immunogen inc  research and development overview key therapeutic areas immunogen inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities immunogen inc  pipeline products glance immunogen inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities immunogen inc  early stage pipeline products preclinical productscombination treatment modalities immunogen inc  drug profiles coltuximab ravtansine product description mechanism of action rd progress imgn product description mechanism of action rd progress mirvetuximab soravtansine product description mechanism of action rd progress huher product description mechanism of action rd progress imgn product description mechanism of action rd progress imgn product description mechanism of action rd progress immunogen inc  pipeline analysis immunogen inc  pipeline products by target immunogen inc  pipeline products by route of administration immunogen inc  pipeline products by molecule type immunogen inc  pipeline products by mechanism of action immunogen inc  recent pipeline updates immunogen inc  dormant projects immunogen inc  discontinued pipeline products discontinued pipeline product profiles ave ave cantuzumab ravtansine coltuximab ravtansine imgn lorvotuzumab mertansine oncolysin b immunogen inc  company statement immunogen inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables immunogen inc key information immunogen inc key facts immunogen inc  pipeline by indication  immunogen inc  pipeline by stage of development  immunogen inc  monotherapy products in pipeline  immunogen inc  partnered products in pipeline  immunogen inc  partnered products combination treatment modalities  immunogen inc  phase ii  immunogen inc  phase i  immunogen inc  preclinical  immunogen inc  pipeline by target  immunogen inc  pipeline by route of administration  immunogen inc  pipeline by molecule type  immunogen inc  pipeline products by mechanism of action  immunogen inc  recent pipeline updates  immunogen inc  dormant developmental projects immunogen inc  discontinued pipeline products  immunogen inc subsidiaries list of figures immunogen inc  pipeline by top  indication  immunogen inc  pipeline by stage of development  immunogen inc  monotherapy products in pipeline  immunogen inc  partnered products in pipeline  immunogen inc  pipeline by top  target  immunogen inc  pipeline by top  route of administration  immunogen inc  pipeline by top  molecule type  immunogen inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     immunogen  pipeline  coltuximab ravtansine twitter go about usmissionexecutive officersboard of directorsin the communitycontact usour adc technologywhat is an adcadc designwith checkpoint inhibitorsour partnerskadcylapipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublicationsinvestorspress releasesevents  presentationscorporate governanceexecutive officersboard of directorscommittee compositionfinancials  filingsstock informationcontact uscareersbenefits about usmissionexecutive officersboard of directorsin the communitycontact usour adc technologywhat is an adcadc designwith checkpoint inhibitorsour partnerskadcylapipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublicationsinvestorspress releasesevents  presentationscorporate governancefinancials  filingsstock informationcontact uscareersbenefits go coltuximab ravtansine coltuximab ravtansine formerly sar is a cdtargeting adc created by immunogen to treat diffuse large bcell lymphoma dlbcl and other bcell malignancies immunogen regained rights to this adc from sanofi in april  coltuximab ravtansine demonstrated evidence of anticancer activity in the treatment of relapsedrefractory dlbcl in the starlyte phase  trial last updated may   pipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublications   immunogen inc sitemap  privacy policy  usage policy you are now leaving this website if you would like to continue click continue cancelcontinue immunogen  pipeline  mirvetuximab soravtansine twitter go about usmissionexecutive officersboard of directorsin the communitycontact usour adc technologywhat is an adcadc designwith checkpoint inhibitorsour partnerskadcylapipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublicationsinvestorspress releasesevents  presentationscorporate governanceexecutive officersboard of directorscommittee compositionfinancials  filingsstock informationcontact uscareersbenefits about usmissionexecutive officersboard of directorsin the communitycontact usour adc technologywhat is an adcadc designwith checkpoint inhibitorsour partnerskadcylapipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublicationsinvestorspress releasesevents  presentationscorporate governancefinancials  filingsstock informationcontact uscareersbenefits go mirvetuximab soravtansine mirvetuximab soravtansine imgn an adc is a potential new treatment for patients with folate receptor alpha frαpositive cancer these include many ovarian cancers as well as other types of solid tumors eg endometrial mirvetuximab soravtansine is immunogens lead program and is in clinical testing in the phase  forward i trial as a single agent for the treatment of platinumresistant ovarian cancer the candidate is also being assessed in combination regimens for both platinumresistant and platinumsensitive disease in the phase b forward ii trial for more information visit wwwclinicaltrialsgov the us food and drug administration granted orphan drug designation to mirvetuximab soravtansine for the treatment of ovarian cancer mirvetuximab soravtansine has also received this designation in the eu asco  poster presentations last updated june  pipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublications   immunogen inc sitemap  privacy policy  usage policy you are now leaving this website if you would like to continue click continue cancelcontinue immunogen inc investors about us mission executive officers board of directors in the community contact us our adc technology what is an adc adc design with checkpoint inhibitors our partners kadcyla pipeline mirvetuximab soravtansine coltuximab ravtansine imgn imgn imgn cancer trials partner compounds publications investors press releases events  presentations corporate governance executive officers board of directors committee composition financials  filings sec filings annual reports quarterly reports key ratios stock information historic stock lookup investment calculator analyst coverage ownership profile contact us careers benefits contact us go investors corporate profile immunogen is a clinicalstage biotechnology company that develops targeted cancer therapeutics using its proprietary antibodydrug conjugate adc technology immunogens lead product candidate mirvetuximab soravtansine is in a phase  trial for frαpositive platinumresistant ovarian cancer and is in phase b testing in combination regimens for earlierstage disease immunogens adc technology is used in roches marketed product kadcyla in other clinicalstage immunogen product candidates and in programs in development by amgen bayer biotest cytomx debiopharm lilly novartis sanofi and takeda nasdaq imgn    jul   at  pm et intraday data provided by esignal press releases jul   immunogen reports recent progress and second quarter  operating results read more jul   immunogen announces conference call to discuss its second quarter  financial results read more events  webcasts jul   at  am et immunogen quarterly update conference call aug   at  am et canaccord genuity growth conference shareholder inquiries inquiries related to the company may be directed to the investor relations department at our headquarters communications related to stock and transfer requirements including lost stock certificates and change of name or address should be directed to the transfer agent corporate headquarters immunogen inc  winter street waltham ma  phone   email infoimmunogencom   corporate counsel mintz levin cohn ferris glovsky and popeo pc boston ma transfer agent and registrar broadridge corporate issuer solutions inc po box  brentwood ny  phone   fax   email shareholderbroadridgecom   independent accountants ernst  young llp boston ma receive email alerts sign up to receive email alerts whenever immunogen inc posts new information to the site just enter your email address and click submit email alerts email alerts snapshot snapshot print print email email share share facebook google linkedin twitter email rss investors press releases events  presentations corporate governance executive officers board of directors committee composition financials  filings sec filings annual reports quarterly reports key ratios stock information historic stock lookup investment calculator analyst coverage ownership profile contact us   immunogen inc sitemap  privacy policy  usage policy you are now leaving this website if you would like to continue click continue cancelcontinue immunogen  pipeline  partner compounds twitter go about usmissionexecutive officersboard of directorsin the communitycontact usour adc technologywhat is an adcadc designwith checkpoint inhibitorsour partnerskadcylapipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublicationsinvestorspress releasesevents  presentationscorporate governanceexecutive officersboard of directorscommittee compositionfinancials  filingsstock informationcontact uscareersbenefits about usmissionexecutive officersboard of directorsin the communitycontact usour adc technologywhat is an adcadc designwith checkpoint inhibitorsour partnerskadcylapipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublicationsinvestorspress releasesevents  presentationscorporate governancefinancials  filingsstock informationcontact uscareersbenefits go partner compounds compounds in clinical testing through our partnerships anetumab ravtansine bay  is a mesothelintargeting adc in development by bayer healthcare for the treatment of mesothelioma it is in a phase  clinical study designed to support registration indatuximab ravtansine bt is an adc that targets cd it is in clinical testing by biotest for the treatment of a variety of cancers that express this target including multiple myeloma triple negative metastatic breast cancer and metastatic bladder cancer we have optin rights for the us isatuximab sar is a therapeutic or naked antibody that is in phase  clinical testing through our collaboration with sanofi sar targets cd and has shown promising activity in early clinical testing when used alone or as part of a combination regimen to treat patients with previously treated multiple myeloma sar is an adc in development by sanofi for the treatment of solid tumors that express ceacam sar is a lamptargeting adc in development by sanofi sar is an adc is in development with sanofi for the treatment of caexpressing cancers which include many breast ovarian cervical lung and pancreatic tumors debio imgn is an adc in development by debiopharm for the treatment of patients with cdpositive bcell malignancies such as nonhodgkin lymphoma nhl amg xxx in clinical testing ly is an fgfrtargeting adc in development by lilly pca is an adc in development by novartis for pcadherinpositive cancershkt is an adc in development by novartis for cdhpositive cancers our partner roche is also conducting clinical trials with kadcyla for additional indications amgen cytomx lilly novartis sanofi and takeda also have certain rights to develop products using our adc technology last updated june  pipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublications   immunogen inc sitemap  privacy policy  usage policy you are now leaving this website if you would like to continue click continue cancelcontinue immunogen  pipeline twitter go about usmissionexecutive officersboard of directorsin the communitycontact usour adc technologywhat is an adcadc designwith checkpoint inhibitorsour partnerskadcylapipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublicationsinvestorspress releasesevents  presentationscorporate governanceexecutive officersboard of directorscommittee compositionfinancials  filingsstock informationcontact uscareersbenefits about usmissionexecutive officersboard of directorsin the communitycontact usour adc technologywhat is an adcadc designwith checkpoint inhibitorsour partnerskadcylapipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublicationsinvestorspress releasesevents  presentationscorporate governancefinancials  filingsstock informationcontact uscareersbenefits go pipeline program cancertypes phases mirvetuximab soravtansine ovarian preclinical phase l phase ll pivotalphase lll endometrial preclinical phase l imgn aml preclinical phase l imgn hematologic malignancies preclinical coltuximab ravtansine nhl preclinical phase l phase ll kadcyla® her mbc ndline preclinical phase l phase ll pivotalphase lll marketed her other preclinical phase l phase ll pivotalphase lll anetumab ravtansine mesothelioma preclinical phase l phase ll indatuximab ravtansine multiple myeloma preclinical phase l phase ll breast bladder preclinical phase l isatuximab multiple myeloma preclinical phase l phase ll phase lll sar solid tumors preclinical phase l sar solid tumors preclinical phase l sar solid tumors preclinical phase l debio imgn nhl preclinical phase l phase ll amg xxx undisclosed preclinical phase l pca pcad cancer preclinical phase l hkt cdh cancer preclinical phase l ly solid tumors preclinical phase l cx undisclosed preclinical tbd undisclosed preclinical earlier stage compounds in development by immunogen and our partners amgen lilly and novartis have licences to additional targets  immunogen  roche  sanofi  biotest  bayer  amgen  novartis  lilly  cytomx  takeda debiopharm kadcyla® is a registered trademark of genentech a member of the roche group  therapeutic antibody nhl nonhodgkin lymphomaaml acute myeloid leukemiammbc metastatic breast cancerbc breast cancer based on information on clinicaltrialsgov or other public disclosures last updated june  pipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublications   immunogen inc sitemap  privacy policy  usage policy you are now leaving this website if you would like to continue click continue cancelcontinue immunogen inc press releases about us mission executive officers board of directors in the community contact us our adc technology what is an adc adc design with checkpoint inhibitors our partners kadcyla pipeline mirvetuximab soravtansine coltuximab ravtansine imgn imgn imgn cancer trials partner compounds publications investors press releases events  presentations corporate governance executive officers board of directors committee composition financials  filings sec filings annual reports quarterly reports key ratios stock information historic stock lookup investment calculator analyst coverage ownership profile contact us careers benefits contact us go press releases year all years         sort by date descending date ascending update   press releases   date title view jul   immunogen reports recent progress and second quarter  operating results data presented at asco support broad potential of mirvetuximab soravtansine in ovarian cancer sanofi and debiopharm transactions strengthen cash position conference call to be held at am et today waltham massbusiness wire immunogen  pdf jul   immunogen announces conference call to discuss its second quarter  financial results waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that the company will host a conference call at  am et on friday july   to discuss its second quarter  finan pdf jun   immunogen presents data from phase i study of imgn in acute myeloid leukemia data demonstrate favorable safety profile with repeat dosing and no doselimiting toxicities dosedependent biological and antileukemia activity observed waltham massbusiness wire immunogen inc nasdaqimgn a leader in the expanding field pdf may   immunogen and sanofi amend license agreements amendments grant sanofi exclusive fullypaid licenses to selected development compounds immunogen to receive  million license fee waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugate pdf may   immunogen announces webcast of presentation at the jefferies global healthcare conference waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that mark enyedy president and chief executive officer will present at the upcoming jefferies  global healthcare conferen pdf may   debiopharm international sa enters the field of antibodydrug conjugates through acquisition of phase ii asset from immunogen transaction adds innovative clinicalstage program to expanding debiopharm portfolio and broadens its clinical development expertise divestiture aligns with immunogens focus on strategic growth initiatives and generates nearterm value lausanne switzerland  waltham mass pdf may   immunogen announces new clinical data with mirvetuximab soravtansine in ovarian cancer to be presented at  asco annual meeting pooled analyses of phase  expansion cohorts demonstrate clinically meaningful activity in patient population being studied in forward i registration trial topline data from forward ii indicate favorable safety and efficacy profile in multiple combinations conference call pdf may   immunogen reports recent progress and first quarter  operating results phase  forward i trial of mirvetuximab soravtansine activated in north america and europe data at aacr and sgo annual meetings highlight patient selection strategy for forward i and breadth of adc expertise mirvetuximab soravtansine safety and efficacy data to be presented at  pdf may   immunogen announces results from mirvetuximab soravtansine phase  firstinhuman doseescalation trial published in cancer data informed dosing in expansion cohorts and phase  forward i registration trial waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that the resu pdf apr   immunogen announces conference call to discuss its first quarter  financial results waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that the company will host a conference call at  am et on friday may   to discuss its first quarter  financial pdf mar   immunogen presents phase  biopsy expansion cohort data at the society of gynecologic oncology annual meeting data confirm use of archival tumor tissue to determine patient selection in forward i waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that data  pdf mar   immunogen announces presentations at aacr annual meeting nine presentations featuring the companys leadership in adcs waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that nine abstracts highlighting the breadt pdf feb   immunogen reports recent progress and operating results for sixmonth period and quarter ended december   first patient enrolled in phase  forward i trial of mirvetuximab soravtansine continued momentum in  with data expected from pipeline programs conference call to be held at am et today waltham massbusiness wire immunogen inc pdf feb   immunogen announces webcasts of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that the following presentations by company management at upcoming investor conferences will be webcast  pdf jan   immunogen announces first patient dosed in forward i phase  study of mirvetuximab soravtansine in platinumresistant ovarian cancer waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that the first patient has been dosed in forward i the companys phase  clinical trial evaluating mirvetuximab soravtansine a pdf jan   immunogen announces conference call to discuss its results for sixmonth period and quarter ended december  waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that the company will host a conference call at  am et on friday february   to discuss immunogens financial res pdf jan   immunogen announces departure of sandra poole waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that sandra poole executive vice president technical operations and commercial development will leave the company at the end pdf dec   immunogen announces mirvetuximab soravtansine phase  expansion cohort results in platinumresistant ovarian cancer published in the journal of clinical oncology positive results form basis for forward i phase  registration trial waltham massbusiness wire immunogen inc nasdaqimgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that results from the phase  pdf dec   immunogen announces webcast of presentation and qa at the th annual j p morgan healthcare conference waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer announced that mark enyedy president and ceo will present at the upcoming th annual j p morgan healthcare conference in san francisco th pdf dec   preclinical data on imgn a novel cdtargeting adc presented at ash annual meeting data demonstrate activity in acute myeloid leukemia models while sparing normal bone marrow waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer announced that precl pdf nov   immunogen to present preclinical data highlighting potential of combining mirvetuximab soravtansine with an immune checkpoint inhibitor at sitc  annual meeting waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced new preclinical data that demonstrate the potential for enhanced activity when combining mirvetuximab soravtansine with immune  pdf nov   immunogen announces preclinical data presentations for two adcs with novel ign payloads at upcoming th ash annual meeting includes oral presentation on cdtargeting adc imgn waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that new preclinical data on the companys nove pdf oct   immunogen reports financial results for quarter ended september  and reviews business highlights phase  forward i trial of mirvetuximab soravtansine on track to begin before year end forward ii trial assessing mirvetuximab soravtansine combinations with avastin® carboplatin doxil® and keytruda® ongoing strategic review completed to strengthen underl pdf oct   immunogen inc announces conference call to discuss its financial results for quarter ended september  waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that the company will host a conference call at  am et on friday october   to discuss immunogens financial resu pdf sep   immunogen completes strategic review to strengthen the organization and drive longterm growth waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced the completion of a strategic review of its operations as a result of this initiative the company will reduce its workforce b pdf aug   immunogen announces departure of chief development officer waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that charles morris mbchb mrcp executive vice president and chief development officer is leaving the company effec pdf aug   immunogen inc announces webcasts of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a leader in the expanding field of antibodydrug conjugates adcs for the treatment of cancer today announced that the following presentations by company management at upcoming investor conferences will be webcast  pdf aug   immunogen reports fourth quarter and fiscal year  financial results and provides quarterly business update − conference call at  am et today  following positive meeting with fda phase  forward i study of mirvetuximab soravtansine in patients with platinumresistant ovarian cancer on track to begin before year end mirvetuximab soravtansine plus avastin pdf jul   immunogen inc announces conference call to discuss its fourth quarter and fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company developing novel antibodydrug conjugate adc therapeutics today announced that the company will host a conference call at  am et on thursday august   to discuss immunogens financial results for the pdf jun   immunogen announces pricing of  million offering of  convertible senior notes due  waltham massbusiness wire immunogen inc nasdaq imgn today announced the pricing of  million aggregate principal amount of its  convertible senior notes due  the notes in a private placement the notes will be offered by the initial purchasers only to qualified institutional buyers  pdf jun   immunogen announces proposed  million offering of convertible senior notes due  waltham massbusiness wire immunogen inc nasdaq imgn today announced its intention to offer and sell to the initial purchasers subject to market and other conditions  million aggregate principal amount of convertible senior notes due  the notes in a private placement the notes  pdf may   immunogen reports efficacy and safety data from a patient cohort of mirvetuximab soravtansine in frαpositive ovarian cancer confirmed objective response rate of  and median progressionfree survival of  months seen in cohort subset mirroring patient population selected for planned phase  study company preparing to meet with fda in early q targeting initiation of phase  study in q  pdf may   immunogen inc announces webcasts of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company developing targeted cancer therapeutics using its proprietary antibodydrug conjugate adc technology today announced that the following presentations by company management at upcoming investor conferences will be pdf apr   immunogen reports third quarter fiscal year  financial results and provides corporate update − conference call at  am et today will include update on mirvetuximab soravtansine the first folate receptor α frαtargeting antibodydrug conjugate adc including the design of the forward i trial − waltham massbusiness wire immunogen  pdf apr   immunogen appoints mark j enyedy as president and chief executive officer  proven leader with deep experience building oncology businesses  waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company developing targeted cancer therapeutics using its proprietary antibodydrug conjugate adc technology today announced that m pdf apr   immunogen announces initiation of clinical testing of firstinclass imgn for acute myeloid leukemia novel cdtargeting product candidate is the first antibodydrug conjugate adc to employ an ign a new type of cancerkilling agent phase  study in acute myeloid leukemia aml is designed to efficiently inform the imgn development pathway waltham pdf apr   immunogen inc announces conference call to discuss its third quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the company will host a conference call at  am et on friday april   to discuss immu pdf apr   daniel junius to retire as president and ceo of immunogen inc  successor expected to be announced shortly  waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapeutics using its antibodydrug conjugate adc technology today announced that daniel junius age  has  pdf feb   immunogen and merck establish collaboration for clinical evaluation of mirvetuximab soravtansine in combination with keytruda® pembrolizumab for the treatment of ovarian cancer − immunogens mirvetuximab soravtansine folate receptor alpha frαtargeting antibodydrug conjugate adc to be assessed in combination with mercks antipd therapy − waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that  pdf feb   immunogen inc announces webcasts of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the following presentations by company management at upcoming investor conferences will b pdf jan   immunogen reports second quarter fiscal year  financial results and provides corporate update − conference call today at  am et − both immunogens forward i and forward ii clinical trials are open for patient enrollment forward i is designed to support an accelerated approval pathway for lead program mirvetuximab soravtansine and forward ii assesses this  pdf jan   immunogen earns milestone with bayers initiation of a phase  clinical study designed to support anetumab ravtansine registration waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapeutics using its antibodydrug conjugate adc technology today announced the company earned a milestone payment with bayers initiation of a global phase  clinical study de pdf jan   immunogen inc announces conference call to discuss its second quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the company will host a conference call at  am et on friday january   to d pdf jan   immunogen announces recent product program advancements and anticipated  events in advance of jp morgan healthcare conference waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapeutics using its antibodydrug conjugate adc technology today announced recent product program advancements and anticipated  events in advance of the th annual jp  pdf jan   immunogen inc announces webcast of presentation and qa at the th annual j p morgan healthcare conference waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that daniel junius president and ceo will present at the upcoming th annual j p morgan healthcare pdf dec   immunogen inc announces oppenheimer th annual healthcare conference webcast waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that david johnston executive vice president and chief financial officer will present at the upcoming pdf dec   immunogen inc announces data presentations at upcoming th ash annual meeting and exposition waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapeutics using its antibodydrug conjugate adc technology today announced the presentation of new preclinical data with the companys experimental therapies imgn  pdf nov   immunogen named one of the boston globes top places to work for third consecutive year waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapeutics using its antibodydrug conjugate adc technology today announced that it has been named one of the boston globes top places to work the company has received this r pdf nov   treatment response to immunogens mirvetuximab soravtansine found to be substantially greater in ovarian cancer with high expression of folate receptor alpha objective response on mirvetuximab soravtansine in nine of ten  patients with high amounts of target on cancer cells majority of these responders remained on treatment for at least  weeks most patients with ovarian cancer found to have high or medium expression of target  pdf oct   immunogen reports first quarter fiscal year  financial results and provides corporate update − conference call today at  am et − level of target expression on patient tumors may have a marked impact on response to mirvetuximab soravtansine immunogens novel folate receptor α frαtargeting antibodydrug conjugate adc data to be reported at  pdf oct   immunogen inc announces conference call to discuss its first quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the company will host a conference call at  am et on tuesday october   to discuss i pdf sep   webcast of the immunogen inc analyst  investor event on september   waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that investors journalists and the general public are invited to listen to a live webcast of the compa pdf sep   immunogen inc announces morgan stanley global healthcare conference webcast waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced the company will participate in the morgan stanley global healthcare conference immunogen president an pdf aug   immunogen inc announces webcast of its analyst and investor event on september   waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that investors journalists and the general public are invited to listen to a live webcast of the compa pdf aug   immunogen inc announces canaccord genuity growth conference webcast waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced the company will participate in the canaccord genuity th annual growth conference immunogen pdf jul   immunogen inc reports fourth quarter and fiscal year  financial results − company provides corporate update and fiscal year  financial guidance − − conference call today at  am et − immunogens wholly owned mirvetuximab soravtansine demonstrates notable singleagent activity in early clinical testing for  pdf jul   immunogen inc announces conference call to discuss its fourth quarter and fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the company will host a conference call at  am et on friday july   to disc pdf jun   immunogens imgn for bcell malignancies demonstrates synergistic activity with rituximab in preclinical models of nonhodgkin lymphoma waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapeutics using its antibodydrug conjugate adc technology today announced the first presentation of findings with the companys cdtargeting adc imgn in combination wi pdf may   immunogens mirvetuximab soravtansine imgn demonstrates notable single agent activity for patients with platinumresistant ovarian cancer objective response rate orr of   as single agent  in patients with folatereceptor alpha frαpositive platinumresistant ovarian cancer majority of responses are ongoing clinical development program advancing expanding waltham massbusiness wire  pdf may   immunogen inc announces clinical data presentations at upcoming asco annual meeting presentations to include initial findings with companys mirvetuximab soravtansine imgn for ovarian cancer and results from roches marianne trial with kadcyla® waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel  pdf may   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the following presentations by company management at upcoming investor conferences will be webcast pdf apr   immunogen inc reports third quarter fiscal year  financial results − conference call today at  am et− the company is investing in its wholly owned product programs including expanding its mirvetuximab soravtansine imgn and imgn clinical programs and developing plans for recently reacquired coltuximab ravtansine sar pdf apr   immunogen inc announces conference call to discuss its third quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the company will host a conference call at  am et on friday april   to discuss immu pdf apr   immunogen inc appoints anna berkenblit md mmsc vice president and chief medical officer waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapies using its antibodydrug conjugate adc technology today announced the appointment of anna berkenblit md mmsc as vice president and chief medical officer dr berkenbl pdf mar   immunogen inc announces  million nondilutive royalty transaction waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapeutics using its antibodydrug conjugate adc technology today announced a  million nondilutive royalty transaction with funds managed by tpg special situations partner pdf mar   takeda licenses rights to use immunogen incs novel antibodydrug conjugate technology cambridge  waltham massbusiness wire takeda pharmaceutical company limited tse and immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapeutics using its stateoftheart antibodydrug conjugate adc technology today announced that takeda has li pdf mar   immunogen inc announces presentations at upcoming aacr annual meeting  waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced the presentations on company and partner programs to be made at the upcoming american association for c pdf feb   immunogen inc announces webcast of presentation at upcoming investor conference waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the following presentation by company management at an upcoming investor conference will  pdf feb   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the following presentations by company management at upcoming investor conferences will be webcast pdf jan   immunogen inc reports second quarter fiscal year  financial results − conference call today at  am et− profit reported for quarter driven by partner activity company reiterates previous financial guidance for fiscal year numerous events expected in  with immunogen and partner product programs  pdf jan   immunogen inc announces conference call to discuss its second quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the company will host a conference call at  am et on friday january   to d pdf jan   immunogen inc announces  outlook for product pipeline waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapies using its antibodydrug conjugate adc technology today announced immunogen expectations for its product pipeline in  that company management will be discussing at t pdf dec   immunogen inc appoints richard j gregory phd as evp chief scientific officer john m lambert phd named evp distinguished research fellow waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapies using its antibodydrug conjugate adc technology today announced the appointment of richard j gregory phd as executive vice president research and chief scientifi pdf dec   immunogen reports roche has provided an update on the marianne trial waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today reported that roche has announced topline results of its phase iii marianne study the  pdf dec   immunogen inc announces webcast of presentation at the rd annual jp morgan healthcare conference waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that daniel junius president and ceo will present at the upcoming rd annual jp morgan healthcare  pdf dec   immunogen inc announces encouraging imgn clinical data presented at th ash annual meeting and exposition imgn achieved objective responses in four of ten  evaluable patients with heavily pretreated diffuse large bcell lymphoma dlbcl  including a complete response  at the dose levels evaluated to date dose finding is ongoing with the maximum tolerated dose mtd not yet esta pdf nov   immunogen inc announces clinical and preclinical data presentations at upcoming th ash annual meeting and exposition waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced the data presentations on company and partner experimental therapies to be made at the upcoming america pdf nov   immunogen inc again named one of the boston globes top places to work waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that it has been named one of the boston globes top places to work the company has received  pdf oct   immunogen inc reports first quarter fiscal year  financial results − conference call today at  am et− advancing pipeline of wholly owned therapeutic candidates imgn in initial evaluation of efficacy in treatment of targeted ovarian and endometrial cancers new imgn clinical data to be reported at ash dosefinding evaluati pdf oct   immunogen inc announces conference call to discuss its first quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the company will host a conference call at  am et on friday october   to d pdf sep   immunogen inc hires sandra e poole as senior vice president of technical operations waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapies using its antibodydrug conjugate adc technology today announced the appointment of sandra e poole as senior vice president technical operations ms poole b pdf sep   immunogen inc announces morgan stanley global healthcare conference webcast waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the company will participate in the morgan stanley global healthcare conference consistent with t pdf aug   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the following presentation by company management at an upcoming investor conference will be webcas pdf aug   immunogen inc reports fourth quarter and fiscal year  financial results −company provides corporate update and fiscal year  financial guidance − − conference call today at  am et− advancing pipeline of wholly owned therapeutic candidates imgn beginning evaluation in target patient populations initial e pdf jul   immunogen inc announces conference call to discuss its fourth quarter and fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the company will host a conference call at  am et on friday august   to discuss immu pdf jun   immunogen inc announces preclinical findings for imgn a potential treatment for acute myeloid leukemia novel antibodydrug conjugate is designed to selectively target and kill cdexpressing acute myeloid leukemia cells including leukemic stem cells while sparing normal cells imgn utilizes one of the companys new dnaacting payload agents dgn  pdf jun   immunogen inc announces favorable starlyte phase ii clinical data with sanofis sar in diffuse large bcell lymphoma sar achieved objective responses well above the study threshold and was found to have a favorable safety profile objective responses reported in patients whose disease had not responded to prior therapy selected for best of asco  pdf may   immunogen inc announces clinical data presentations at upcoming th annual meeting of asco abstracts made public today provide insight on biological effects seen at low doses with imgn and on observed activity threshold for imgn abstracts also add to growing body of data on the significance of partner compounds including the findings reported on the activity and  pdf may   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the following presentations by company management at upcoming investor conferences will be webcast pdf apr   immunogen inc reports third quarter fiscal year  financial results and provides corporate update −quarterly conference call today at  am et− wholly owned product candidates  advancing with expanding news flow expected kadcyla® sales growing  launches in european union starting beyond kadcyla  encouraging initial clinical findings now reported with six other compounds in development  pdf apr   immunogen inc announces conference call to discuss its third quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the company will host a conference call at  am et on friday april   to discuss  pdf apr   immunogen inc announces first clinical findings with refined dosing strategy for imgn initial findings show new dosing approach for imgn achieves objective data presented at american association for cancer research annual meeting waltham mass  san diegobusiness wire immunogen inc nasdaq imgn a biotechnolo pdf mar   immunogen inc announces presentations by company scientists at upcoming aacr annual meeting waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced the presentations scheduled to be made by company scientists at the american association for cancer res pdf feb   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the following presentations by company management at upcoming investor conferences will be webcast pdf feb   immunogen inc appoints ellie harrison as chief human resources officer waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapies using its antibodydrug conjugate adc technology today announced the appointment of ellie harrison as vice president and chief human resources officer ms har pdf feb   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the following presentations by company management at upcoming investor conferences will be webcast pdf jan   immunogen inc appoints eric guempel as vice president of product strategy and program management waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapies using its industry leading antibodydrug conjugate adc technology today announced the appointment of eric guempel as vice president of product strategy and pro pdf jan   immunogen inc reports second quarter fiscal year  financial results and provides corporate update −quarterly conference call today at  am et− progress with all three wholly owned immunogen compounds in clinical testing  imgn imgn imgn decision made to discontinue imgn development marked increase in partner activity in latte pdf jan   immunogen inc announces conference call to discuss its second quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the company will host a conference call at  am et on friday january   to d pdf jan   cytomx therapeutics and immunogen inc announce strategic collaboration to develop probodydrug conjugates against cancer targets — collaboration enables creation of pdcs using cytomxs probody platform and immunogens adc technology — south san francisco  waltham massbusiness wire cytomx therapeutics the probody™ therapeutics company and immunogen inc nasdaq imgn a biotechno pdf jan   immunogen inc announces webcast of presentation at the nd annual jp morgan healthcare conference waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapies using its antibodydrug conjugate adc technology today announced that daniel junius president and ceo will present at the upcoming nd annual jp morgan healthcare  pdf dec   immunogen inc appoints david johnston as chief financial officer waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapies using its industry leading antibodydrug conjugate adc technology today announced the appointment of david johnston as executive vice president and chief financial offi pdf dec   immunogen inc announces activity reported with sar plus rituxan in difficulttotreat patient population waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapies using its antibodydrug conjugate adc technology today announced the presentation of clinical findings with sar coltuximab ravtansine used in combination pdf dec   immunogen inc announces favorable initial safety and response findings for cdtargeting anticancer compound sar initial data from first clinical trial featured in oral presentation at american society of hematology ash annual meeting selected for best of ash objective responses — including complete responses — reported in patients with extensively pretreated multiple myeloma m pdf dec   immunogen inc announces clinical data presentations at upcoming th ash annual meeting and exposition waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodybased anticancer therapeutics today provided information on the clinical data presentations related to the company to be made at the upcoming american society of hematology  pdf nov   immunogen inc announces approval of roches kadcyla® in the european union european commission has approved kadcyla® for marketing in the eu which triggers a  million milestone payment to immunogen kadcyla comprises roches trastuzumab antibody with immunogens linker and dm cellkilling agent waltham mass pdf nov   immunogen inc named one of the boston globes top places to work waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology announced today that it has again been named one of the boston globes top places to work the pdf nov   immunogen inc announces fifth new license agreement in  waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapeutics today announced that novartis has licensed the exclusive right to use the companys antibodydrug conjugate adc technology to develop anticancer therapeutics to an u pdf nov   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its proprietary antibodydrug conjugate adc technology today announced that the following presentations by company management at upcoming investor conferences wil pdf nov   immunogen inc announces discontinuation of imgn study in smallcell lung cancer sclc waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology announced today the decision to stop the imgn phase ii sclc study following the recommendation of the trials independent da pdf nov   immunogen inc initiates phase i testing of its egfrtargeting adc imgn — novel antibodydrug conjugate adc is a potential new treatment for lung head and neck and other egfrpositive solid tumors including ones not effectively treated with egfrdirected therapies today — waltham massbusiness wire immunogen inc nasdaq imgn a biotec pdf oct   immunogen inc reports first quarter fiscal year  financial results and provides quarterly update −quarterly conference call today at  am et− waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today reported financial res pdf oct   immunogen inc reports on additions to its industryleading adc technology portfolio at aacrncieortc conference waltham massbusiness wire immunogen inc nasdaq imgn today reported on additions to the companys portfolio of antibodydrug conjugate adc technologies at the aacrncieortc international conference on molecular targets and cancer therapeutics meeting being held in boston ma of parti pdf oct   immunogen inc announces sar clinical findings reported at aacrncieortc conference first clinical data reported for this novel antibodydrug conjugate adc for ovarian breast and other epithelial cancers first of four partner compounds with clinical data presentations expected this quarter waltham massbusiness wire  pdf oct   immunogen inc announces conference call to discuss its first quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that the company will host a conference call at  am et on friday october   to discuss im pdf oct   immunogen inc announces presentations at upcoming aacrncieortc anticancer conference first clinical data to be reported for sar further expanding the extensive body of data reported with immunogens maytansinoid antibodydrug conjugate adc technology presentations on new adc technologies including a new class of payload agents highlight immunogens continui pdf oct   immunogen inc announces new license agreement waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its antibodydrug conjugate adc technology today announced that novartis has licensed the exclusive right to use the companys adc technology to develop anticancer  pdf sep   immunogen inc announces results from kadcyla® phase iii trial thresa being presented today at the european cancer congress roches kadcyla found to significantly extend duration of progressionfree survival in patients with advanced herpositive breast cancer in second large randomized trial kadcyla comprises roches trastuzumab antibody and immunogens adc technology it has been approved for marketing  pdf sep   immunogen inc announces positive regulatory decisions for roches kadcyla® in the european union and japan chmp has issued a positive opinion for kadcyla with the european commission decision expected by the end of  the japanese mhlw has approved kadcyla for marketing in japan which triggers a  million milestone payment to immunogen kadcyla comprises roches tr pdf sep   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its proprietary antibodydrug conjugate adc technology today announced that the following presentations by company management at upcoming investor conferences wil pdf aug   immunogen inc announces executive change waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops novel anticancer therapeutics using its proprietary antibodydrug conjugate adc technology today announced that gregory d perry executive vice president and chief financial officer has provided  pdf aug   immunogen inc reports fourth quarter and fiscal year  financial results and provides fiscal year  financial guidance and corporate update kadcyla® sales off to strong start decision on approval in european union thresa phase iii data presentation expected by roche in h immunogen progress with its proprietary pipeline includes advancement of third wholly owned product candidate for solid tumors i pdf aug   immunogen inc announces fda acceptance of ind for companys novel egfrtargeting adc imgn novel antibodydrug conjugate adc imgn on track to begin human clinical testing for treatment of egfrpositive tumors in q imgn is a potential new treatment for lung head and neck and other egfrpositive solid tumors including ones not effectively treated with egfrdir pdf jul   immunogen inc announces conference call to discuss its fourth quarter and fiscal year  financial results — webcast of presentation at upcoming investor conference also announced — waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics using its targeted antibody payload tap antibodydrug con pdf jun   first clinical data presented with imgn immunogen incs potential new therapy for ovarian and other cancers first clinical findings presented with immunogens folate receptor α frαtargeting antibodydrug conjugate adc imgn preliminary evidence of activity seen in dosefinding portion of trial waltham massbusiness wire immuno pdf may   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics using its targeted antibody payload tap antibodydrug conjugate adc technology today announced that the following presentations by company management at upcoming i pdf may   immunogen inc announces webcast of presentation at upcoming investor conference waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics using its targeted antibody payload tap antibodydrug conjugate adc technology today announced that gregory perry executive vice president and chief financial officer wil pdf apr   immunogen inc reports third quarter fiscal year  financial results and provides quarterly update first product with immunogens adc technology kadcyla™ launched in the us multiple additional markets indications expected three novel wholly owned immunogen compounds advancing in clinical testing with the first clinical data for imgn to be reported at asco preclinical pdf apr   immunogen inc announces conference call to discuss its third quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapeutics today announced that the company will host a conference call at  am et on friday april   to discuss immunogens financial results for the threemonth pe pdf apr   webcast of the immunogen inc analyst and investor community meeting on april   waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics today announced that investors journalists and the general public are invited to listen to a live webcast of the companys analyst and investor community meeting on april  pdf apr   immunogen inc announces preclinical findings with its imgn product candidate for the treatment of egfroverexpressing cancers novel antibodydrug conjugate adc can kill epidermal growth factor receptor egfroverexpressing cancer cells via two mechanisms — egfrinhibition and direct cellkilling in preclinical testing imgn was highly active against egfroverexpressing cancer cells including tho pdf mar   immunogen inc announces webcast of its analyst and investor community meeting on april   waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics today announced that investors journalists and the general public are invited to listen to a live webcast of the companys analyst and investor community meeting on april   pdf feb   immunogen inc announces fda approval of kadcyla adotrastuzumab emtansine also known as tdm product demonstrates the power of immunogens targeted antibody payload tap technology — first antibodydrug conjugate approved for a solid tumor indication compound to be marketed in the us by genentech a member of the roche group under the brand name kadcyla™ was pr pdf feb   immunogen inc attains patient enrollment milestone in imgn north trial waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer therapeutics today announced that it has completed patient enrollment in the first stage of its north twostage phase ii trial the north trial is assessing the companys  pdf feb   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics using its targeted antibody payload tap technology and antibody expertise today announced that the following presentations by company management at upcoming investor conferen pdf jan   immunogen inc reports second quarter fiscal year  financial results and provides quarterly update trastuzumab emtansine tdm marketing applications are under review in the us and europe us application has priority review status with a pdufa date of february   in  immunogen expects to report clinical findings with its three lead wholly owned compounds and to advance pdf jan   immunogen inc announces conference call to discuss its second quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer products using its targeted antibody payload tap technology and antibody expertise today announced that the company will host a conference call at  am et on friday january pdf jan   immunogen inc announces webcast of presentation at the st annual jp morgan healthcare conference waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics using its targeted antibody payload tap technology and antibody expertise today announced that daniel junius president and ceo will present at the upcoming st annual  pdf dec   amgen takes third license for rights to use immunogens tap technology waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics using its targeted antibody payload tap technology and antibody expertise today announced that amgen has licensed the exclusive right to use the companys maytansino pdf dec   immunogen inc announces imgn clinical data presented at ash benefit seen in both lenalidomidenaïve and lenalidomiderefractory multiple myeloma waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics using its targeted antibody payload tap technology and pdf dec   immunogen inc announces webcast of presentation at the oppenheimer rd annual healthcare conference waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics using its targeted antibody payload tap technology and antibody expertise today announced that daniel junius president and ceo will present at the upcoming oppenheimer rd pdf dec   immunogen inc announces clinical data presentations at the th ash annual meeting and exposition waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics using its targeted antibody payload tap technology and antibody expertise today announced that there will be clinical data presentations on two compounds that utiliz pdf nov   immunogen inc appoints dr charles morris as chief development officer — dr morris brings to the company extensive experience leading the successful development and registration of novel anticancer compounds — waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therape pdf nov   immunogen inc announces fda has granted priority review status to the trastuzumab emtansine tdm marketing application waltham massbusiness wire immunogen inc nasdaq imgn a biopharmaceutical company that develops anticancer products using its targeted antibody payload tap technology and antibody expertise today announced that genentech a member of the roche group has disclosed that the us fo pdf nov   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biopharmaceutical company that develops anticancer therapeutics using its antibody expertise and targeted antibody payload tap technology today announced that the following presentations by company management at upcoming inve pdf oct   immunogen inc reports first quarter fiscal year  financial results and provides quarterly update marketing applications submitted for trastuzumab emtansine tdm in the us and europe meaningful clinical data expected to be reported in coming year — for immunogen compounds tdm and other partner compounds immunogen well positioned to advance its who pdf oct   immunogen inc announces conference call to discuss its first quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biopharmaceutical company that develops anticancer products using its targeted antibody payload tap technology and antibody expertise today announced that the company will host a conference call at  am et on friday oct pdf oct   immunogen inc announces overall survival data reported for trastuzumab emtansine tdm phase iii emilia trial trastuzumab emtansine reduced risk of death by  compared to the standardofcare treatment arm of the trial findings being reported at the esmo  congress european society of medical oncology and published in new england journal of medicine walth pdf sep   immunogen inc announces presentation of new imgn clinical data phase i evaluation presented established imgn dose being used in phase ii assessment — the north trial — for firstline treatment of smallcell lung cancer sclc imgn able to be administered at full singleagent dose in combination regimen assessed  pdf sep   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics using its antibody expertise and targeted antibody payload tap technology today announced that the following presentations by company management at upcoming investor pdf aug   immunogen inc announces trastuzumab emtansine tdm significantly improved survival in the emilia phase iii trial trastuzumab emtansine significantly improved overall survival os as well as progressionfree survival pfs in its lead phase iii trial emilia separately the marketing application for trastuzumab emtansine has been submitted to the us fda and one is to be submitted shortly to  pdf aug   immunogen inc reports fourth quarter and fiscal year  financial results and provides corporate update and fiscal year  guidance positive phase iii results with trastuzumab emtansine tdm were presented in a plenary session at asco in june roche intends to use these data to apply in  for marketing approval of the compound for the use evaluated immunogen expects up to three additional partner compounds t pdf jul   immunogen inc announces conference call to discuss its fourth quarter and fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer products using its antibody expertise and targeted antibody payload tap technology today announced that the company will host a conference call at  am et on friday august  pdf jul   immunogen inc prices public offering of common stock waltham massbusiness wire immunogen inc nasdaq imgn announced today that it has priced an underwritten public offering of  million shares of its common stock at a price to the public of  per share gross proceeds are expected to be approximately  million before deducting the underwriting  pdf jul   immunogen inc announces proposed public offering of common stock waltham massbusiness wire immunogen inc nasdaq imgn announced today that it intends to offer for sale its common stock in an underwritten public offering the offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as t pdf jul   immunogen inc initiates phase i trial of imgn in ovarian cancer and other solid tumors overexpressing its folate receptor target — folate receptor  folrtargeting compound is second novel immunogen product candidate to enter clinic this year — waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics using its antibody  pdf jun   immunogen inc announces presentation of new clinical data for sar waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company today announced the presentation of new clinical data for the investigational compound sar at the american society of clinical oncology asco annual meeting taking place in chicago il sar uses  pdf jun   immunogen inc announces development of trastuzumab emtansine for early stage herpositive breast cancer waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company with a proprietary targeted antibody payload tap technology today announced that roche is implementing a threepronged approach to developing trastuzumab emtansine tdm for early stage herpositive  pdf jun   immunogen inc announces results from trastuzumab emtansine tdm emilia phase iii trial waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company with a proprietary targeted antibody payload tap technology today announced results from the trastuzumab emtansine phase iii emilia trial conducted by roche trastuzumab emtansine comprises immunogens dm cancer pdf may   immunogen inc announces presentations at  asco annual meeting on product candidates with the companys tap technology — trastuzumab emtansine tdm emilia phase iii data selected for plenary session sar data and additional trastuzumab emtansine data also being reported — waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops target pdf may   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodybased anticancer products today announced that the following presentations by company management at upcoming investor conferences will be webcast bank of america mer pdf apr   immunogen inc reports third quarter fiscal year  financial results and provides quarterly update trastuzumab emtansine tdm progress includes achievement of progressionfree survival pfs endpoint in lead phase iii trial for her metastatic breast cancer data from this trial and the phase ii safety trial in neoadjuvant setting submitted to asco for presentation  pdf apr   immunogen inc announces conference call to discuss its third quarter fiscal year  financial results waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodybased anticancer products today announced that the company will host a conference call at  am et on friday april   to discuss immunogens financial results for the thr pdf apr   immunogen inc announces the ind is now active for its folatereceptor targeting anticancer compound imgn potential new therapeutic for ovarian cancer nonsmall cell lung cancer nsclc and other solid tumors which overexpress folate receptor  folr achievement of active ind for imgn closely follows start of patient dosing with imgn and initiation of phase ii testing with  pdf apr   immunogen inc initiates phase i trial in nonhodgkins lymphoma with its novel imgn anticancer compound — first of two unique immunogen product candidates expected to enter clinic in  — waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops anticancer therapeutics using its antibody expertise and targeted antibo pdf mar   immunogen inc announces conference call at  am et march   to discuss todays favorable announcements about trastuzumab emtansine tdm and about imgn waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer products today announced that it will host a conference call at  am et on friday march   to discuss the two releases issued by the company earlier today  pdf mar   immunogen inc announces initiation of phase ii evaluation of its imgn product candidate north trial assesses impact of adding imgn to standard care for firstline treatment of smallcell lung cancer sclc trial includes planned interim analysis to enable early decisions on next steps to advancement waltham massbusiness wire  pdf mar   immunogen inc announces positive results in trastuzumab emtansine tdm emilia phase iii trial roche has announced lead phase iii trial with trastuzumab emtansine has met progressionfree survival endpoint plans to apply for marketing approval of trastuzumab emtansine in us and europe study data being submitted for presentation at major medical meeting  pdf mar   immunogen inc announces webcast of presentation at the cowen nd annual health care conference waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodybased anticancer products today announced that its presentation at the cowen nd annual health care conference at  am et on march   will be webcast live  pdf feb   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wire immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodybased anticancer products today announced that the following presentations by company management at upcoming investor conferences will be webcast  pdf jan   immunogen inc announces addition of kristine peterson and dean mitchell to its board of directors waltham mass jan   globe newswire  immunogen inc nasdaqimgn a biotechnology company that develops targeted anticancer therapeutics using its antibody expertise today announced the addition of kristine peterson and dean mitchell to the companys board of directors both kris and dean have more than  years of experience i pdf jan   immunogen inc reports second quarter fiscal year  financial results and provides quarterly update product pipeline progress includes continued advancement of trastuzumab emtansine tdm toward phase iii data reporting and marketing submission in  initiation of sar multistudy phase ii program and progression of imgn toward phase ii start     the product pipeline continues to expand through progress by both immunogen and par pdf jan   immunogen inc announces conference call to discuss its second quarter fiscal year  financial results waltham massbusiness wirejan    pdf jan   immunogen inc announces webcast of presentation at the jp morgan th annual healthcare conference waltham mass jan   globe newswire  immunogen inc nasdaqimgn a biotechnology company that develops targeted antibodybased anticancer products today announced that its presentation at the jp morgan th annual healthcare conference at  pm pt on january   will be webcast live the webcast of this presentation can pdf dec   immunogen inc announces antibodydrug conjugate collaboration with lilly agreement provides lilly a leader in the development of important cancer therapeutics with access to immunogens tap technology immunogen to receive  million upfront milestone payments potentially totaling  million — for each target — and royalties on any commercial sales waltham mass dec   globe newswire    pdf dec   immunogen inc announces webcast of presentation at the oppenheimer nd annual healthcare conference waltham mass dec   globe newswire  immunogen inc nasdaqimgn a biotechnology company that develops targeted antibodybased anticancer products today announced that its presentation at the oppenheimer nd annual healthcare conference at  pm et on december   will be webcast live the webcast of this presentation ca pdf nov   immunogen inc earns milestone payment from amgen with ind achievement for second tap compound waltham mass nov   globe newswire  immunogen inc nasdaqimgn a biotechnology company that develops targeted anticancer products using its antibody expertise and targeted antibody payload tap technology today announced that the investigational new drug ind application submitted by amgen for a second tap compound is now activ pdf nov   immunogen inc named one of the boston globes  top places to work waltham mass nov   globe newswire  immunogen inc nasdaqimgn a biotechnology company that develops targeted antibodybased anticancer products today announced that it has been named one of the boston globes  top places to work the boston globe engaged workplacedynamics specialists in employee engagement and retention pdf nov   immunogen inc earns milestone from amgen with ind achievement waltham mass nov   globe newswire  immunogen inc nasdaqimgn a biotechnology company that develops targeted anticancer products using its antibody expertise and targeted antibody payload tap technology today announced that an investigational new drug ind application amgen submitted for a novel anticancer compound that utiliz pdf nov   immunogen inc announces webcast of presentations at upcoming investor conferences waltham mass nov   globe newswire  immunogen inc nasdaqimgn a biotechnology company that develops targeted antibodybased anticancer products today announced that company management will present at two investor conferences in the coming weeks credit suisse healthcare conference am mst am est on november    pdf oct   immunogen inc reports first quarter fiscal year  financial results and provides quarterly update lead product candidates have notable developments while pipeline continues to expand recent progress includes positive trastuzumab emtansine tdm clinical data advancement of sar to phase ii testing progress with lead wholly owned compounds and advancement of bay  partner compound to phase i waltham mass oct   gl pdf oct   immunogen inc announces conference call to discuss its first quarter fiscal year  financial results waltham mass oct   business wire  immunogen inc nasdaq imgn a biotechnology company that dev pdf oct   immunogen inc earns milestone with start of sar phase ii testing waltham mass oct   globe newswire  immunogen inc nasdaqimgn a biotechnology company that develops targeted anticancer products using its antibody expertise and targeted antibody payload tap technology today announced that sar has started phase ii testing this event triggers a  million milestone payment to immunogen s pdf oct   immunogen inc announces webcast of presentation at the th annual newsmakers in the biotech industry conference waltham mass oct   globe newswire  immunogen inc nasdaqimgn a biotechnology company that develops targeted antibodybased anticancer products today announced that its presentation at the th annual newsmakers in the biotech industry conference at  am et on october   will be webcast live the webcast of this pr pdf sep   tdm significantly improved progressionfree survival compared to standard of care for previously untreated herpositive metastatic breast cancer waltham mass sept   globe newswire  immunogen inc nasdaqimgn a biotechnology company that develops targeted anticancer products using its tap technology today announced findings from the first randomized clinical trial conducted with trastuzumab emtansine also known as tdm trastuzumab emtansine consists of immunogens  pdf sep   immunogen inc announces submission of ind for wholly owned product candidate for nonhodgkins lymphoma waltham mass sep   globenewswire via comtex immunogen inc nasdaqimgn a biotechnology company that develops targeted anticancer products using its antibody expertise and targeted antibody payload tap technology today announced its submission of the investigational new drug ind application for its imgn product ca pdf aug   immunogen inc announces webcast of presentations at upcoming investor conferences waltham mass aug   globenewswire via comtex immunogen inc nasdaqimgn a biotechnology company that develops targeted antibodybased anticancer products using its antibody expertise and targeted antibody payload tap technology today announced that company management will present at three investor conferences in the co pdf aug   immunogen inc announces webcast of presentation at the canaccord genuity st annual growth conference waltham mass aug   business wire  immunogen inc nasdaq imgn a biotechnology company that d pdf aug   immunogen inc reports fourth quarter and fiscal year  financial results and provides corporate update and fiscal year  guidance waltham mass aug   business wire  immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer  pdf jul   immunogen inc announces conference call to discuss its fourth quarter and fiscal year  financial results waltham mass jul   business wire  immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer  pdf jun   immunogen inc earns milestone with bay  ind submission waltham mass jun   business wire  immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodyba pdf jun   immunogen inc announces positive clinical data presented on imgn in the treatment of multiple myeloma waltham mass jun   business wire  immunogen inc nasdaq imgn a biotechnology company that d pdf jun   immunogen inc announces presentation of favorable sar interim clinical data at asco waltham mass jun   business wire  immunogen inc nasdaq imgn a biotechnology company that d pdf jun   immunogen inc announces webcast of presentation at jefferies  global healthcare conference waltham massimmunogen inc nasdaq imgn a biotechnology company that develops targeted antibodybased anticancer products using its antibody expertise and targeted antibody payload tap technology today announced that executive vice president and cfo gregory perry will present at the jefferies  global healthcare conference pdf may   immunogen inc announces clinical presentations at the asco  annual meeting waltham mass may   business wire  immunogen inc nasdaq imgn a biotechnology company that  pdf may   immunogen inc prices public offering of common stock waltham mass may   business wire  immunogen inc nasdaq imgn announced today that it has priced an underwritten public offering of  shares of its common stock at a price to the public of  per share gross proceeds are expected to be approximately  million before deducting the underwriting discounts and comm pdf may   immunogen inc announces proposed public offering of common stock waltham mass may   business wire  immunogen inc nasdaq imgn announced today that it intends to offer shares of its common stock in an underwritten public offering the offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size  pdf may   immunogen inc announces webcast of presentation at bank of america merrill lynch  health care conference waltham mass may   business wire  immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodybased anticancer products using its antibody expertise and targeted antibody payload tap technology today announced that president and ceo daniel junius will present at the bank pdf apr   immunogen inc reports third quarter fiscal year  financial results and provides quarterly update waltham mass apr   business wire immunogen inc nasdaq imgn a biotech pdf apr   immunogen inc announces conference call to discuss its third quarter fiscal year  financial results waltham mass apr   business wire immunogen inc nasdaq imgn a biotechnology company that develops t pdf apr   tdm significantly improved progressionfree survival in randomized phase ii trial waltham mass apr   business wire immunogen inc nasdaq imgn a biotechn pdf apr   immunogen inc announces first data for its novel therapeutic for ovarian cancer and other carcinomas waltham mass apr   business wire immunogen inc nasdaq imgn a biotech pdf apr   immunogen inc announces first data for its imgn product candidate for nonhodgkins lymphoma waltham mass apr   business wire immunogen inc nasdaq imgn a biotechnology company that develops  pdf mar   immunogen inc announces presentations at the nd annual meeting of the american association for cancer research waltham mass mar   business wire immunogen inc nasdaq imgn a biotechn pdf feb   immunogen inc announces webcast of presentations at upcoming investor conferences waltham massbusiness wireimmunogen inc nasdaq imgn a biotechnology pdf feb   immunogen inc announces webcast of presentations at upcoming investor conferences waltham mass feb   business wire  immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodybased anticancer products using its antibody expertise and targeted antibody payload tap technology today announced that company management will present at two investor conferences next week a live webcast o pdf feb   immunogen inc announces webcast of its investment community meeting on february   waltham mass feb   business wire  immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodyba pdf jan   immunogen inc reports second quarter fiscal year  financial results waltham mass jan   business wire immunogen inc nasdaq imgn a biotechnology company that develops  pdf jan   immunogen inc announces conference call to discuss its second quarter fiscal year  financial results waltham mass jan   business wire immunogen inc nasdaqimgn a biotechno pdf jan   immunogen inc appoints theresa wingrove phd as vice president regulatory affairs waltham mass jan   business wire immunogen inc nasdaq imgn a biotechnology company that develops t pdf jan   immunogen inc announces webcast of presentation at jp morgan th annual healthcare conference waltham mass jan   business wire immunogen inc nasdaq imgn a biotechn pdf dec   immunogen inc announces clinical data for tdm used in combination with pertuzumab for firstline treatment of her metastatic breast cancer waltham mass dec   business wire immunogen inc nasdaq imgn a biopharmaceutical pdf dec   immunogen inc announces presentation of positive initial clinical data for imgn used in a combination regimen for multiple myeloma waltham mass dec   business wire immunogen inc nasdaq imgn a biotechn pdf nov   immunogen inc announces initiation of randomized clinical trial evaluating imgn for firstline treatment of smallcell lung cancer waltham mass nov   business wire immunogen inc nasdaq imgn a biotechn pdf nov   immunogen inc announces presentation of encouraging clinical data for imgn at eortcnciaacr symposium on molecular targets and cancer therapeutics waltham mass nov   business wire immunogen inc nasdaq imgn a biotechn pdf nov   immunogen inc announces clinical data presentations at the nd ash annual meeting and exposition waltham mass nov   business wire  immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodyba pdf nov   immunogen inc announces webcast of presentation at lazard capital markets th annual healthcare conference waltham mass nov   business wire immunogen inc nasdaq imgn a biotechn pdf nov   immunogen inc announces presentations at the nd eortcnciaacr symposium on molecular targets and cancer therapeutics waltham mass nov   business wire immunogen inc nasdaq imgn a biotechn pdf oct   immunogen inc reports first quarter fiscal year  financial results waltham mass oct   business wire immunogen inc nasdaq imgn a biotechnology company that develops t pdf oct   immunogen inc announces conference call to discuss its first quarter fiscal year  financial results waltham mass oct   business wire immunogen inc nasdaqimgn a biotechno pdf oct   immunogen inc announces webcast of presentations at upcoming investor conferences waltham mass oct   business wire immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodybased anticancer products using its antibody expertise and targeted antibody payload tap technology today announced that company management will present at two investor conferences in the coming weeks the li pdf oct   immunogen inc announces presentation of encouraging clinical data for lorvotuzumab mertansine at esmo annual meeting waltham mass oct   business wire  immunogen inc nasdaq imgn a biopharmaceutical company that develops targeted anticancer therapeutics using its targeted antibody payload tap technology today announced the presentation of encouraging clinical data for the companys lorvotuzumab mertansine imgn targeted anticancer comp pdf oct   immunogen inc announces conference call at  am et october   to discuss new collaboration and updated guidance for fiscal year  waltham mass oct   business wire  immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodybased anticancer products today announced that it will host a conference call at  am et on monday october   to discuss the companys new collaboration announced this morning and its updated financia pdf oct   immunogen inc announces updated guidance for  fiscal year waltham mass oct   business wire  immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodybased anticancer products today announced updated guidance for the companys fiscal year ending june   net cash used in operations is expected to be between  and  million with a net loss e pdf oct   immunogen inc announces collaboration for rights to use immunogens tap technology waltham mass oct   business wire  immunogen inc nasdaq imgn announced today that it has entered into a collaboration agreement with novartis to discover and develop targeted anticancer therapeutics using antibodies to several antigen targets to be named by novartis under this agreement novartis will pay a  millio pdf oct   immunogen inc announces positive interim results in randomized clinical trial comparing trastuzumabdm vs standard firstline therapy for firstline her metastatic breast cancer waltham mass oct   business wire immunogen inc nasdaq imgn a biotech pdf sep   immunogen inc announces start of sar clinical testing waltham mass sep   business wire immunogen inc nasdaq imgn a biotechnology company that develops t pdf sep   immunogen inc announces webcast of presentations at multiple investor conferences in september waltham mass sep   business wire immunogen inc nasdaq imgn a pdf aug   genentech receives refuse to file letter from fda for tdm waltham massbusiness wireimmunogen inc nasdaq imgn a  pdf aug   immunogen incannounces orphan drug designation granted to lorvotuzumab mertansine for treatment of smallcell lung cancer waltham mass aug   business wire immunogen inc nasdaq imgn a biotechnology company that develops  pdf aug   immunogen inc reports fourth quarter and fiscal year  financial results waltham mass aug   business wire immunogen inc nasdaq imgn a biotechnology company that develops t pdf jul   immunogen inc announces webcast of presentation at upcoming investor conferences waltham mass jul   business wire immunogen inc nasdaq imgn an pdf jul   immunogen inc announces conference call to discuss its fourth quarter and fiscal year  financial results waltham mass jul   business wire  immunogen inc nasdaqimgn a biotechnology company that develops targeted anticancer products today announced that the company will host a conference call at  pm et on wednesday august   to discuss immunogens financial results for the three pdf jul   marketing application submitted to fda for trastuzumabdm pdf jun   immunogen inc earns milestone with start of sar clinical trial waltham mass jun   business wire immunogen inc nasdaq imgn a biotechnology company that develops targeted antibodybased anticancer products today announced that sanofiaventis has initiated a phase i clinical trial with sar an investigational antibody that targets cancer cells  pdf jun   immunogen inc announces vice president promotions in product development waltham mass jun   business wire immunogen inc nasdaq imgn a biopharmaceutical company that develops targeted anticancer therapeutics today announced the promotion to vice president of two executive directors  godfrey amphlett phd and robert j lutz phd  who have played central roles in establishing immunogens high pdf jun   immunogen inc announces encouraging imgn clinical data reported at asco waltham ma june   – immunogen inc nasdaq imgn a biopharmaceutical company that develops targeted anticancer therapeutics today announced the presentation of the first clinical data for the company’s imgn anticancer compound at the  annual meeting of the american society of clinical oncology asco being held in  pdf jun   immunogen inc announces presentation of clinical data for trastuzumabdm at asco annual meeting waltham mass jun   business wire immunogen inc nasdaq imgn a biopharmaceutical company that develops targeted anticancer therapeutics today announced the presentation of clinical data from a phase ibii trial conducted by roche and genentech to investigate the safety and preliminary efficacy of trastuzumabdm tdm used i pdf jun   immunogen inc announces webcast of presentation at upcoming investor conferences waltham mass jun   business wire immunogen inc nasdaq imgn announced today that daniel junius president and ceo will present at two investor conferences next week these presentations will be webcast live and can be accessed through the investor information section of the companys website wwwimmunogencom an archive of pdf may   immunogen inc announces clinical data presentations at upcoming asco annual meeting waltham mass may   business wire immunogen inc nasdaq imgn a biopharmaceutical company that develops targeted anticancer therapeutics announced today that there will be several clinical data presentations for compounds utilizing the companys targeted antibody payload tap technology at the  pdf may   immunogen inc announces exercise of overallotment option waltham mass may   business wire immunogen inc nasdaq imgn a biopharmaceutical company that develops targeted anticancer therapeutics announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase  shares of common stock at a public o pdf may   immunogen inc announces webcast of presentation at the bank of america merrill lynch health care conference waltham mass may   business wire immunogen inc nasdaq imgn is scheduled to present at the bank of america merrill lynch health care conference at  pm et on may   the conference is being held at the grand hyatt new york immunogens presentation will be webcast live and can be pdf may   immunogen inc prices public offering of common stock waltham mass may   business wire immunogen inc nasdaq imgn a biopharmaceutical company that develops targeted anticancer therapeutics announced today that it has priced a public offering of  shares of its common stock at a price of  per share net proceeds after underwriting discounts and commissions and expen pdf may   immunogen inc announces proposed public offering of common stock waltham mass may   business wire immunogen inc nasdaq imgn a biopharmaceutical company that develops targeted anticancer therapeutics announced today that it intends to offer subject to market and other conditions  shares of its common stock in an underwritten public offering immunogen  pdf apr   immunogen inc reports third quarter fiscal year  financial results waltham mass apr   business wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer products using its antibody expertise and targeted antibody payload tap technology today announced financial results for the threemonth period ended march    the third quarter of the companys   pdf apr   immunogen inc announces conference call to discuss its third quarter fiscal year  financial results waltham mass apr   business wire immunogen inc nasdaqimgn a biotechnology company that develops targeted anticancer products today announced that will host a conference call at  pm et on thursday april   to discuss the companys financial results for the threemonth period ended march    the third quarter pdf apr   immunogen inc announces favorable update provided by roche related to its trastuzumabdm regulatory plans waltham mass apr   business wire immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer products today announced that roche has provided a favorable update related to its plans to apply for marketing approval of trastuzumabdm tdm in the us tdm comprises immunogens dm cancerce pdf mar   immunogen inc announces webcast of presentation at the  barclays capital global healthcare conference waltham mass mar   business wire  immunogen inc nasdaq imgn is scheduled to present at the  barclays capital global healthcare conference at  pm et on march   the conference is being held at the loews miami beach hotel in miami beach florida immunogens presentation wil pdf mar   immunogen inc announces orphan drug designation granted to imgn for treatment of merkel cell carcinoma by us fda and eu comp waltham mass mar   business wire  immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer products using its antibody expertise and targeted antibody payload tap technology today announced that the us food and drug administration fda has granted orphan drug designation to its imgn compound  pdf mar   immunogen inc announces webcast of presentations at upcoming investor conferences waltham mass mar   business wire  immunogen inc nasdaq imgn announced today that management will participate in two upcoming investor conferences with live webcasts rbc capital markets healthcare conference new york palace hotel new york ny gregory perry senior vice president and chief financial office pdf feb   immunogen inc announces webcast of its investment community meeting on february   waltham mass feb   business wire  immunogen inc nasdaq imgn a biopharmaceuticals company that develops targeted anticancer therapeutics using its targeted antibody payload tap technology invites investors journalists and the general public to listen to a live webcast of the companys investment community meeting on februa pdf feb   immunogen inc announces webcast of presentation at the th annual bio ceo  investor conference waltham mass feb   business wire  immunogen inc nasdaq imgn is scheduled to present at the th annual bio ceo  investor conference at  pm et on february   the conference is being held at the waldorfastoria hotel in new york city immunogens presentation will be webcast pdf jan   immunogen inc reports second quarter fiscal year  financial results waltham mass jan   business wire  immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer products using its antibody expertise and targeted antibody payload tap technology today announced financial results for the threemonth period ended december    the  pdf jan   immunogen inc announces conference call to discuss its second quarter fiscal year  financial results waltham mass jan   business wire  immunogen inc nasdaq imgn a biotechnology company that develops targeted anticancer products today announced that will host a conference call at  pm et on thursday january   to discuss the companys financial results for the threemonth period ended december    the seco pdf jan   immunogen inc announces webcast of presentation at the th annual jp morgan healthcare conference waltham mass jan   business wire  immunogen inc nasdaq imgn is scheduled to present at the th annual jp morgan healthcare conference at  am pst on january   the conference is being held at the westin st francis hotel in san francisco ca immunogens presentation will be webcast live and can be accessed throug pdf email alerts email alerts snapshot snapshot print print email email share share facebook google linkedin twitter email rss investors press releases events  presentations corporate governance executive officers board of directors committee composition financials  filings sec filings annual reports quarterly reports key ratios stock information historic stock lookup investment calculator analyst coverage ownership profile contact us   immunogen inc sitemap  privacy policy  usage policy you are now leaving this website if you would like to continue click continue cancelcontinue pharmaceuticals market research reports  pharmaceuticals industry analysis  marketresearchcom about us solutions resources ebookswhite papers slideshares videos blog contact us register log in my account logout browse research my cart menu   close   x browse about us solutions resources contact us log out register log in market research » life sciences pharmaceuticals market research reports  industry analysis the pharmaceutical industry is directly impacted by the research conducted with prescription drugs vaccines and otc drugs being manufactured based on findings from the study of life sciences clinical trials are conducted to ensure that products being developed are tested on how well they work on individuals affected by the diseases or conditions they are created to treat the market research available can provide investors and analysts credible information on the direction of pharmaceuticals anesthesia drug delivery pricing regulations and policy being developed to ensure that knowledgeable and informed decisions are made regarding industry direction show more show less filter your search filter your search anesthesia  antibiotic  biopharmaceuticals  biopharmacology  clinical nutrition  clinical trial  country overviews  dietary supplements  diseases  conditions  drug delivery  drug discovery  general pharmaceuticals  generics drugs  manufacturing packaging  detailing  overthecounter drugs  pharmaceuticals company reports  pharmacy  distribution  prescription drugs  pricing  regulation  policy  research  development  technology  therapeutic area  vaccines  global  europe  asia  north america  south america  africa  oceania  middle east  caribbean  central america  research assistance us  intl  join alert me now receive biweekly email alerts on new research sign up find out more on our blog pharmaceuticals industry research  market reports sort by title az title za price lowtohigh price hightolow date date older first refine your search close window refine your search title publisher keyword priceusd to date any date last month last  months last  months last year last  years region all regions africa    algeria    angola    benin    botswana    burkina faso    burundi    cameroon    cape verde    central african republic    chad    comoros    the congo    the congo    cote divoire    djibouti    egypt    equatorial guinea    eritrea    ethiopia    gabon    the gambia    ghana    guinea    guineabissau    kenya    lesotho    liberia    libya    madagascar    malawi    mali    mauritania    mauritius    mayotte    morocco    mozambique    namibia    niger    nigeria    reunion    rwanda    sao tome and principe    senegal    seychelles    sierra leone    somalia    south africa    south sudan    sudan    swaziland    tanzania    togo    tunisia    uganda    western sahara    zambia    zimbabwe asia    afghanistan    armenia    azerbaijan    bangladesh    bhutan    brunei    cambodia    china    cocos keeling islands    east timor    georgia    hong kong    india    indonesia    japan    kazakhstan    kyrgyzstan    laos    macau    malaysia    maldives    mongolia    myanmar    nepal    north korea    pakistan    papua new guinea    philippines    russia    singapore    south korea    sri lanka    taiwan    tajikistan    thailand    turkey    turkmenistan    uzbekistan    vietnam caribbean    anguilla    antigua and barbuda    aruba    the bahamas    barbados    british virgin islands    cayman islands    cuba    curacao    dominica    dominican republic    grenada    guadeloupe    haiti    jamaica    martinique    montserrat    netherlands antilles    puerto rico    saint kitts and nevis    saint lucia    saint vincent and the grenadines    sint maarten saint maarten    trinidad and tobago    turks and caicos islands    virgin islands central america    belize    costa rica    el salvador    guatemala    honduras    nicaragua    panama europe    albania    andorra    austria    belarus    belgium    bosnia and herzegovina    bulgaria    croatia    czech republic    denmark    estonia    faroe islands    finland    france    germany    gibraltar    greece    guernsey    hungary    iceland    ireland    isle of man    italy    jersey    kosovo    latvia    liechtenstein    lithuania    luxembourg    macedonia    malta    moldova    monaco    netherlands    norway    poland    portugal    romania    san marino    scotland    serbia and montenegro    slovakia    slovenia    spain    sweden    switzerland    ukraine    united kingdom global middle east    bahrain    cyprus    gaza strip    iran    iraq    israel    jordan    kuwait    lebanon    oman    palestinian territories    qatar    saudi arabia    syria    united arab emirates    yemen north america    bermuda    canada    greenland    mexico    united states oceania    american samoa    australia    cook islands    fiji    french polynesia    guam    kiribati    marshall islands    micronesia federated states of    nauru    new caledonia    new zealand    niue    norfolk island    northern mariana islands    palau    samoa    solomon islands    tonga    tuvalu    vanuatu south america    argentina    bolivia    brazil    chile    colombia    ecuador    falkland islands    french guiana    guyana    paraguay    peru    suriname    uruguay    venezuela search global cancer diagnostics market overview  test volume and sales forecasts by country laboratory universe jul    usd  etiology of major types of cancer estimates of the number of laboratories performing cancer tests as well as tenyear test volume and sales forecasts by country contains  pages and  tables please note the  read more europe hepatitis markers testing market  supplier shares and sales segment forecasts for  immunodiagnostic and nat procedures  hospitals blood banks public health labs commercial labs physician offices jul    usd  analysis of the hepatitis diagnostics market in europe france germany italy spain uk current scientific views on the hepatitis definition epidemiology and etiology are reviewed the report provides the fiveyear test volume and sales forecasts  read more tumor markers testing instrumentation review cancer diagnostic analyzers and strategic profiles of leading suppliers jul    usd  testing the report also presents strategic assessments of current and emerging suppliers of cancer diagnostic products including their sales product portfolios distribution tactics technological knowhow new products in rampd collaborative arrangements and business strategies contains  read more cancer diagnostic instrumentation review tumor marker testing analyzers and strategic profiles of leading suppliers jul    usd  testing the report also presents strategic assessments of current and emerging suppliers of tumor marker diagnostic products including their sales product portfolios distribution tactics technological knowhow new products in rampd collaborative arrangements and business strategies  read more global hepatitis markers testing market  supplier shares and sales segment forecasts for  immunodiagnostic and nat procedures  hospitals blood banks public health labs commercial labs physician offices jul    usd  analysis of the hepatitis diagnostics market in the us europe france germany italy spain uk and japan current scientific views on the hepatitis definition epidemiology and etiology are reviewed the report provides the year test  read more momenta pharmaceuticals performance capabilities goals and strategies in the global pharmaceutical market jul    usd  development and implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing  read more allergan performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more bayer performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more eli lilly performance capabilities goals and strategies in the global pharmaceutical market jul    usd  development and implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing  read more merck performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more pfizer performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more perrigo performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more akorn performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more valeant pharmaceuticals performance capabilities goals and strategies in the global pharmaceutical market jul    usd  development and implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing  read more zoetis performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more mylan performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more astrazeneca performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more novartis performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more roche performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more sanofi performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more teva pharmaceuticals performance capabilities goals and strategies in the global pharmaceutical market jul    usd  development and implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing  read more endo pharmaceuticals performance capabilities goals and strategies in the global pharmaceutical market jul    usd  development and implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing  read more mallinckrodt performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more dr reddys laboratories performance capabilities goals and strategies in the global pharmaceutical market jul    usd  to the development and implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions  read more glaxosmithkline performance capabilities goals and strategies in the global pharmaceutical market jul    usd  implementation of effective marketing and rd programs in the dynamic and fragmented pharmaceutical market besieged by intense competition and rapid change of technological innovations the ability to anticipate new product introductions and marketing strategies is  read more  prev           next  start new browse consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media company reports reports by country view all market areas view all publishers immunogen  changing lives twitter go about usmissionexecutive officersboard of directorsin the communitycontact usour adc technologywhat is an adcadc designwith checkpoint inhibitorsour partnerskadcylapipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublicationsinvestorspress releasesevents  presentationscorporate governanceexecutive officersboard of directorscommittee compositionfinancials  filingsstock informationcontact uscareersbenefits about usmissionexecutive officersboard of directorsin the communitycontact usour adc technologywhat is an adcadc designwith checkpoint inhibitorsour partnerskadcylapipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublicationsinvestorspress releasesevents  presentationscorporate governancefinancials  filingsstock informationcontact uscareersbenefits go we created our antibodydrug conjugate adc technology to achieve better therapies for people with cancer it is used in roches kadcyla® which is making a difference for people today learn more our work changes us  enabling us to use our special skills and expertise to achieve new therapies for people with cancer a growing number of compounds with our technology are being evaluated in the clinic to treat many different types of cancer news  events eha  firstinhuman data on imgn in acute myeloid leukemia presented at congress read more asco  mirvetuximab soravtansine safety and efficacy data presented at asco annual meeting read more asco  mirvetuximab soravtansine findings from ph  patient ovarian cancer expansion cohort reported read more clinical trial of imgn  rituximab is open for enrollmentread more immunogen inc one of the boston globestop places to work  recognized for thirdconsecutive yearread more follow us on twitter clinical trials clinical trials can provide an opportunity for appropriate patients to receive experimental therapies several trials with immunogen adcs are currently enrolling patientslearn more press releases july   immunogen reports recent progress and second quarter  operating results july   immunogen announces conference call to discuss its second quarter  financial results view all   immunogen inc sitemap  privacy policy  usage policy you are now leaving this website if you would like to continue click continue cancelcontinue